177 related articles for article (PubMed ID: 33230879)
1. Characterization and prognostic implication of delayed complete response in AL amyloidosis.
Muchtar E; Gertz MA; Kumar SK; Lacy MQ; Leung N; Buadi FK; Dingli D; Hayman SR; Go RS; Kapoor P; Gonsalves W; Kourelis TV; Warsame R; Lisa Hwa Y; Fonder A; Hobbs M; Russell S; Lust JA; Siddiqui M; Vincent Rajkumar S; Kyle RA; Dispenzieri A
Eur J Haematol; 2021 Mar; 106(3):354-361. PubMed ID: 33230879
[TBL] [Abstract][Full Text] [Related]
2. Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Manwani R; Hegenbart U; Mahmood S; Sachchithanantham S; Kyriakou C; Yong K; Popat R; Rabin N; Whelan C; Dittrich T; Kimmich C; Hawkins P; Schönland S; Wechalekar A
Blood Cancer J; 2018 Nov; 8(11):101. PubMed ID: 30397193
[TBL] [Abstract][Full Text] [Related]
3. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis.
Vaxman I; Sidiqi MH; Al Saleh AS; Kumar S; Muchtar E; Dispenzieri A; Buadi F; Dingli D; Lacy M; Hayman S; Leung N; Gonsalves W; Kourelis T; Warsame R; Hogan W; Gertz M
Bone Marrow Transplant; 2021 Apr; 56(4):928-935. PubMed ID: 33208916
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.
Sidiqi MH; Aljama MA; Jevremovic D; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Gonsalves WI; Kumar S; Kapoor P; Kourelis T; Leung N; Hogan WJ; Gertz MA
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2360-2364. PubMed ID: 29964192
[TBL] [Abstract][Full Text] [Related]
5. Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
Kastritis E; Misra A; Gurskyte L; Kroi F; Verhoek A; Vermeulen J; Ammann E; Lam A; Cote S; Wechalekar AD
Hematology; 2023 Dec; 28(1):2157581. PubMed ID: 36607151
[TBL] [Abstract][Full Text] [Related]
6. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of minimal residual disease assessed by multiparameter flow cytometry in amyloid light chain amyloidosis.
Li X; Huang B; Liu J; Chen M; Gu J; Li J
J Cancer Res Clin Oncol; 2022 Apr; 148(4):913-919. PubMed ID: 33966111
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Havasi A; Heybeli C; Leung N; Angel-Korman A; Sanchorawala V; Cohen O; Wechalekar A; Bridoux F; Jaffer I; Gutgarts V; Hassoun H; Levinson M; Rosenbaum C; Milani P; Palladini G; Merlini G; Hegenbart U; Schönland S; Veelken K; Pogrebinsky A; Doros G; Landau H
Blood Cancer J; 2022 Aug; 12(8):119. PubMed ID: 35982035
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
Martinez-Naharro A; Patel R; Kotecha T; Karia N; Ioannou A; Petrie A; Chacko LA; Razvi Y; Ravichandran S; Brown J; Law S; Quarta C; Mahmood S; Wisniowski B; Pica S; Sachchithanantham S; Lachmann HJ; Moon JC; Knight DS; Whelan C; Venneri L; Xue H; Kellman P; Gillmore JD; Hawkins PN; Wechalekar AD; Fontana M
Eur Heart J; 2022 Dec; 43(45):4722-4735. PubMed ID: 36239754
[TBL] [Abstract][Full Text] [Related]
10. [Treatment options and prognosis in newly diagnosed multiple myeloma patients].
Wang L; Tang W; Wang Y; Xu L; Zhao WL; Wu W; Chen YB; Shen ZX; Hu J
Zhonghua Xue Ye Xue Za Zhi; 2011 May; 32(5):308-12. PubMed ID: 21729598
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-based induction followed by stem cell transplantation in light chain amyloidosis: results of the multicenter HOVON 104 trial.
Minnema MC; Nasserinejad K; Hazenberg B; Hegenbart U; Vlummens P; Ypma PF; Kröger N; Wu KL; Kersten MJ; Schaafsma MR; Croockewit S; de Waal E; Zweegman S; Tick L; Broijl A; Koene H; Bos G; Sonneveld P; Schönland S
Haematologica; 2019 Nov; 104(11):2274-2282. PubMed ID: 30923094
[TBL] [Abstract][Full Text] [Related]
12. Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis.
Sidana S; Sidiqi MH; Dispenzieri A; Buadi FK; Lacy MQ; Muchtar E; Dingli D; Hayman SR; Gonsalves WI; Kapoor P; Leung N; Warsame R; Kourelis TV; Wolf RC; Hogan WJ; Kumar SK; Gertz MA
Am J Hematol; 2019 Sep; 94(9):1020-1026. PubMed ID: 31254301
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
14. Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.
Jimenez-Zepeda VH; Lee H; McCulloch S; Tay J; Duggan P; Neri P; Bahlis N
Amyloid; 2021 Sep; 28(3):182-188. PubMed ID: 34096429
[TBL] [Abstract][Full Text] [Related]
15. A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosis.
Sidana S; Milani P; Binder M; Basset M; Tandon N; Foli A; Dispenzieri A; Gertz MA; Hayman SR; Buadi FK; Lacy MQ; Kapoor P; Leung N; Rajkumar SV; Merlini G; Palladini G; Kumar SK
Blood Cancer J; 2020 Apr; 10(4):41. PubMed ID: 32286270
[TBL] [Abstract][Full Text] [Related]
16. Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.
Sidana S; Muchtar E; Sidiqi MH; Jevremovic D; Dispenzieri A; Gonsalves W; Buadi F; Lacy MQ; Hayman SR; Kourelis T; Kapoor P; Go RS; Warsame R; Leung N; Rajkumar SV; Kyle RA; Gertz MA; Kumar SK
Am J Hematol; 2020 May; 95(5):497-502. PubMed ID: 32010993
[TBL] [Abstract][Full Text] [Related]
17. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
18. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.
Rodríguez-Lobato LG; Fernández de Larrea C; Cibeira MT; Tovar N; Isola I; Aróstegui JI; Rosiñol L; Díaz T; Lozano E; Yagüe J; Bladé J
Amyloid; 2017 Dec; 24(4):245-252. PubMed ID: 29052436
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Patients with Light Chain Amyloidosis Who Had Autologous Stem Cell Transplantation with 3 or More Organs Involved.
Al Saleh AS; Sidiqi MH; Muchtar E; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Warsame RM; Gonsalves WI; Kourelis TV; Hogan WJ; Hayman SR; Kapoor P; Kumar SK; Gertz MA
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1520-1525. PubMed ID: 31054986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
